Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:BNC2-UHRF2

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: BNC2-UHRF2
	FusionPDB ID: 9980
	FusionGDB2.0 ID: 9980
		Hgene	Tgene
	Gene symbol	BNC2	UHRF2
	Gene ID	54796	115426
	Gene name	basonuclin 2	ubiquitin like with PHD and ring finger domains 2
	Synonyms	BSN2\|LUTO	NIRF\|RNF107\|TDRD23\|URF2
	Cytomap	9p22.3-p22.2	9p24.1
	Type of gene	protein-coding	protein-coding
	Description	zinc finger protein basonuclin-2	E3 ubiquitin-protein ligase UHRF2Np95-like ring finger proteinRING finger protein 107RING-type E3 ubiquitin transferase UHRF2np95/ICBP90-like RING finger proteinnuclear protein 97nuclear zinc finger protein NP97ubiquitin-like PHD and RING finger do
	Modification date	20200313	20200313
	UniProtAcc	Q6ZN30 Main function of 5'-partner protein: FUNCTION: Probable transcription factor specific for skin keratinocytes. May play a role in the differentiation of spermatozoa and oocytes (PubMed:14988505). May also play an important role in early urinary-tract development (PubMed:31051115). {ECO:0000269\|PubMed:14988505, ECO:0000269\|PubMed:31051115}.	.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000380666, ENST00000380667, ENST00000380672, ENST00000471301, ENST00000545497,	ENST00000485617, ENST00000276893, ENST00000381373,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	12 X 16 X 6=1152	14 X 11 X 8=1232
	# samples	16	16
	** MAII score	log2(16/1152*10)=-2.84799690655495 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(16/1232*10)=-2.94485844580754 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Fusion gene context	PubMed: BNC2 [Title/Abstract] AND UHRF2 [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: BNC2 [Title/Abstract] AND UHRF2 [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	BNC2(16870644)-UHRF2(6420912), # samples:1
Anticipated loss of major functional domain due to fusion event.	BNC2-UHRF2 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. BNC2-UHRF2 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. BNC2-UHRF2 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. BNC2-UHRF2 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Tgene	UHRF2	GO:0016567	protein ubiquitination	14741369
Tgene	UHRF2	GO:0051865	protein autoubiquitination	14741369
Tgene	UHRF2	GO:0071158	positive regulation of cell cycle arrest	15178429

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr9:16870644/chr9:6420912)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across BNC2 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across UHRF2 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000380672	BNC2	chr9	16870644	-	ENST00000276893	UHRF2	chr9	6420912	+	3192	61	58	2316	752
ENST00000380672	BNC2	chr9	16870644	-	ENST00000381373	UHRF2	chr9	6420912	+	637	61	58	318	86
ENST00000380667	BNC2	chr9	16870644	-	ENST00000276893	UHRF2	chr9	6420912	+	3217	86	14	2341	775
ENST00000380667	BNC2	chr9	16870644	-	ENST00000381373	UHRF2	chr9	6420912	+	662	86	14	343	109
ENST00000380666	BNC2	chr9	16870644	-	ENST00000276893	UHRF2	chr9	6420912	+	3274	143	71	2398	775
ENST00000380666	BNC2	chr9	16870644	-	ENST00000381373	UHRF2	chr9	6420912	+	719	143	71	400	109

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000380672	ENST00000276893	BNC2	chr9	16870644	-	UHRF2	chr9	6420912	+	0.00010758	0.99989235
ENST00000380672	ENST00000381373	BNC2	chr9	16870644	-	UHRF2	chr9	6420912	+	0.29925567	0.7007444
ENST00000380667	ENST00000276893	BNC2	chr9	16870644	-	UHRF2	chr9	6420912	+	0.000109578	0.99989045
ENST00000380667	ENST00000381373	BNC2	chr9	16870644	-	UHRF2	chr9	6420912	+	0.28980055	0.7101994
ENST00000380666	ENST00000276893	BNC2	chr9	16870644	-	UHRF2	chr9	6420912	+	0.000112517	0.99988747
ENST00000380666	ENST00000381373	BNC2	chr9	16870644	-	UHRF2	chr9	6420912	+	0.18227217	0.81772786

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for BNC2-UHRF2

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
BNC2	chr9	16870644	UHRF2	chr9	6420912	143	24	EAGAALDNQHAEMLENGYTLFDYDVG
BNC2	chr9	16870644	UHRF2	chr9	6420912	86	24	EAGAALDNQHAEMLENGYTLFDYDVG

Top

Potential FusionNeoAntigen Information of BNC2-UHRF2 in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

BNC2-UHRF2_16870644_6420912.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-B44:03	AEMLENGY	0.9993	0.9037	10	18
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-B18:01	AEMLENGY	0.993	0.6562	10	18
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-B45:01	AEMLENGYT	0.9548	0.7208	10	19
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-B35:08	HAEMLENGY	0.798	0.7012	9	18
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-B35:01	HAEMLENGY	0.7946	0.7038	9	18
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-B35:03	EMLENGYTL	0.4804	0.7644	11	20
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-B35:04	EMLENGYTL	0.3766	0.8017	11	20
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-B35:02	EMLENGYTL	0.3766	0.8017	11	20
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-B08:01	EMLENGYTL	0.3513	0.7311	11	20
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-B39:01	EMLENGYTL	0.2914	0.7615	11	20
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-B44:03	AEMLENGYTL	0.9963	0.9259	10	20
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-B13:01	AEMLENGYTL	0.995	0.7321	10	20
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-B45:01	AEMLENGYTL	0.936	0.7633	10	20
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-B39:13	AEMLENGYTL	0.8567	0.7256	10	20
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-B41:01	AEMLENGYTL	0.6998	0.9521	10	20
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-B44:03	AEMLENGYTLF	0.9998	0.9298	10	21
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-C04:10	MLENGYTLF	0.9981	0.5893	12	21
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-C04:07	MLENGYTLF	0.998	0.5936	12	21
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-C05:09	MLENGYTLF	0.9975	0.9195	12	21
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-B15:31	HAEMLENGY	0.8161	0.6408	9	18
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-B15:21	EMLENGYTL	0.464	0.8292	11	20
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-B35:12	EMLENGYTL	0.3766	0.8017	11	20
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-B15:31	EMLENGYTL	0.2769	0.6964	11	20
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-B39:05	EMLENGYTL	0.2041	0.7141	11	20
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-C05:09	ALDNQHAEML	1	0.9479	4	14
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-A02:07	ALDNQHAEML	0.9447	0.6017	4	14
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-B39:08	AEMLENGYTL	0.9342	0.662	10	20
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-B44:26	AEMLENGY	0.9993	0.9037	10	18
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-B44:07	AEMLENGY	0.9993	0.9037	10	18
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-B44:13	AEMLENGY	0.9993	0.9037	10	18
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-B18:06	AEMLENGY	0.9932	0.6534	10	18
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-B18:05	AEMLENGY	0.993	0.6562	10	18
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-B18:11	AEMLENGY	0.9684	0.6178	10	18
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-C04:01	MLENGYTLF	0.998	0.5936	12	21
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-C04:03	MLENGYTLF	0.9976	0.6453	12	21
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-C05:01	MLENGYTLF	0.9975	0.9195	12	21
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-B35:77	HAEMLENGY	0.7946	0.7038	9	18
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-B35:20	HAEMLENGY	0.7831	0.7451	9	18
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-B35:23	HAEMLENGY	0.7786	0.6765	9	18
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-B35:24	HAEMLENGY	0.6163	0.7246	9	18
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-B35:11	HAEMLENGY	0.564	0.6848	9	18
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-B35:13	EMLENGYTL	0.4575	0.7712	11	20
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-B39:11	EMLENGYTL	0.4269	0.6352	11	20
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-B08:12	EMLENGYTL	0.3771	0.7711	11	20
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-B35:09	EMLENGYTL	0.3766	0.8017	11	20
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-B08:18	EMLENGYTL	0.3513	0.7311	11	20
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-C05:01	ALDNQHAEML	1	0.9479	4	14
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-B40:04	AEMLENGYTL	0.9978	0.5512	10	20
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-B44:26	AEMLENGYTL	0.9963	0.9259	10	20
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-B44:13	AEMLENGYTL	0.9963	0.9259	10	20
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-B44:07	AEMLENGYTL	0.9963	0.9259	10	20
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-B15:13	EMLENGYTLF	0.9303	0.6137	11	21
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-B39:02	AEMLENGYTL	0.8909	0.7308	10	20
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-B41:03	AEMLENGYTL	0.7914	0.6492	10	20
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-B44:26	AEMLENGYTLF	0.9998	0.9298	10	21
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-B44:13	AEMLENGYTLF	0.9998	0.9298	10	21
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-B44:07	AEMLENGYTLF	0.9998	0.9298	10	21
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-B35:13	HAEMLENGYTL	0.993	0.7627	9	20
BNC2-UHRF2	chr9	16870644	chr9	6420912	143	HLA-B35:13	AALDNQHAEML	0.9879	0.9018	3	14

Top

Potential FusionNeoAntigen Information of BNC2-UHRF2 in HLA II

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene

Hchr

Hbp

Tgene

Tchr

Tbp

HLA II

FusionNeoAntigen peptide

Neoantigen start (at BP 13)

Neoantigen end (at BP 13)

Top

Fusion breakpoint peptide structures of BNC2-UHRF2

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
1278	DNQHAEMLENGYTL	BNC2	UHRF2	chr9	16870644	chr9	6420912	143

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of BNC2-UHRF2

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	1278	DNQHAEMLENGYTL	-7.15543	-7.26883
HLA-B14:02	3BVN	1278	DNQHAEMLENGYTL	-4.77435	-5.80965
HLA-B52:01	3W39	1278	DNQHAEMLENGYTL	-6.80875	-6.92215
HLA-B52:01	3W39	1278	DNQHAEMLENGYTL	-4.20386	-5.23916
HLA-A11:01	4UQ2	1278	DNQHAEMLENGYTL	-7.5194	-8.5547
HLA-A11:01	4UQ2	1278	DNQHAEMLENGYTL	-6.9601	-7.0735
HLA-A24:02	5HGA	1278	DNQHAEMLENGYTL	-7.52403	-7.63743
HLA-A24:02	5HGA	1278	DNQHAEMLENGYTL	-5.82433	-6.85963
HLA-B27:05	6PYJ	1278	DNQHAEMLENGYTL	-3.28285	-4.31815
HLA-B44:05	3DX8	1278	DNQHAEMLENGYTL	-5.91172	-6.94702
HLA-B44:05	3DX8	1278	DNQHAEMLENGYTL	-4.24346	-4.35686

Top

Vaccine Design for the FusionNeoAntigens of BNC2-UHRF2

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
BNC2-UHRF2	chr9	16870644	chr9	6420912	10	18	AEMLENGY	GCCGAGATGTTGGAAAATGGATAT
BNC2-UHRF2	chr9	16870644	chr9	6420912	10	19	AEMLENGYT	GCCGAGATGTTGGAAAATGGATATACC
BNC2-UHRF2	chr9	16870644	chr9	6420912	10	20	AEMLENGYTL	GCCGAGATGTTGGAAAATGGATATACCTTA
BNC2-UHRF2	chr9	16870644	chr9	6420912	10	21	AEMLENGYTLF	GCCGAGATGTTGGAAAATGGATATACCTTATTT
BNC2-UHRF2	chr9	16870644	chr9	6420912	11	20	EMLENGYTL	GAGATGTTGGAAAATGGATATACCTTA
BNC2-UHRF2	chr9	16870644	chr9	6420912	11	21	EMLENGYTLF	GAGATGTTGGAAAATGGATATACCTTATTT
BNC2-UHRF2	chr9	16870644	chr9	6420912	12	21	MLENGYTLF	ATGTTGGAAAATGGATATACCTTATTT
BNC2-UHRF2	chr9	16870644	chr9	6420912	3	14	AALDNQHAEML	GCTGCACTTGACAACCAGCATGCCGAGATGTTG
BNC2-UHRF2	chr9	16870644	chr9	6420912	4	14	ALDNQHAEML	GCACTTGACAACCAGCATGCCGAGATGTTG
BNC2-UHRF2	chr9	16870644	chr9	6420912	9	18	HAEMLENGY	CATGCCGAGATGTTGGAAAATGGATAT
BNC2-UHRF2	chr9	16870644	chr9	6420912	9	20	HAEMLENGYTL	CATGCCGAGATGTTGGAAAATGGATATACCTTA

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene

Hchr

Hbp

Tchr

Tbp

Start in +/-13AA

End in +/-13AA

FusionNeoAntigen peptide

FusionNEoAntigen RNA sequence

Top

Information of the samples that have these potential fusion neoantigens of BNC2-UHRF2

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
SARC	BNC2-UHRF2	chr9	16870644	ENST00000380666	chr9	6420912	ENST00000276893	TCGA-DX-AB2E-01A

Top

Potential target of CAR-T therapy development for BNC2-UHRF2

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to BNC2-UHRF2

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to BNC2-UHRF2

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)